CAPPED BONUS-ZERTIFIKAT - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 13:38:59 2024-05-17 EDT | ||
| 596.9 EUR | -0.08% |
|
| Current month | -1.47% | ||
| 1 month | -0.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 596.9 | -0.08% |
| 24-05-16 | 597.4 | +0.02% |
| 24-05-15 | 597.2 | -0.23% |
| 24-05-14 | 598.6 | -0.23% |
| 24-05-13 | 600 | -0.18% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 01:38 pm
More quotesStatic data
| Product type | Bonus- und Teilschutz-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Citi
|
| WKN | KJ32G0 |
| ISIN | DE000KJ32G03 |
| Date issued | 2023-12-27 |
| Strike | 667 $ |
| Maturity | 2024-12-19 (214 Days) |
| Parity | 1 : 1 |
| Emission price | 508.5 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 605.8 € |
|---|---|
| Lowest since issue | 510.2 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
